The revenue miss and adverse patent ruling are near-term headwinds, but EDIT-401's preclinical momentum could drive upside if early human data is positive. Monitor for first-in-human trial initiation and proof-of-concept data by year-end 2026; the Jefferies conference on June 4 may provide further pipeline updates.
Price Chart
Executive Summary
Editas Medicine reported Q1 2026 EPS of -$0.26, slightly worse than the -$0.24 consensus (a miss), while revenue of $2.8M fell short of the $5.9M estimate. The company highlighted progress with its lead in vivo candidate EDIT-401, but also disclosed an adverse USPTO ruling reaffirming the Broad Institute's CRISPR/Cas9 patent position, creating legal overhang. Cash burn continues with $123.6M remaining, expected to fund operations into Q3 2027.
Key Financial Metrics
Key Facts
- Q1 2026 EPS: -$0.26 vs consensus -$0.24 (miss of 8.3%)
- Q1 2026 revenue: $2.8M vs consensus $5.9M (miss of 52.5%)
- Net loss narrowed to $25.0M from $76.1M YoY, driven by restructuring and discontinuation of reni-cel program
- Cash and equivalents: $123.6M, down from $146.6M at year-end 2025
- USPTO reaffirmed Broad Institute's patent position in CRISPR/Cas9 interference, adverse for Editas
- EDIT-401 preclinical data shows >90% LDL-C reduction; first-in-human trial expected later in 2026 with proof-of-concept data by year-end
- Company expects cash runway into Q3 2027
Financial Impact
Revenue miss of ~$3.1M (52.5% below consensus); EPS miss of $0.02 (8.3% below consensus); cash burn of $23.0M in Q1
Risk Factors
- Adverse USPTO patent ruling creates uncertainty around CRISPR/Cas9 licensing and potential royalty obligations
- Revenue miss of 52.5% vs consensus signals lack of near-term commercial revenue
- Cash burn rate implies limited runway beyond Q3 2027 without additional financing
- EDIT-401 is still preclinical; clinical failure or delay would eliminate pipeline value
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3287494 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 8, 2026 18d ago | 8-K | $2.84 | awaiting T+20 | — | $2.40 (−15.49%) |
Sep 9, 2026 6w ago | EFFECT | $2.77 $2.75 | ▼ −0.72% | ▼ −2.92% | $2.40 (−13.36%) |
Jun 11, 2026 19w ago | Institutional Cluster | $2.44 $3.30 | ▲ +35.25% | ▲ +33.35% | $2.40 (−1.64%) |
May 26, 2026 21w ago | 424B5 | $3.57 $2.74 | ▲ +23.25% | ▲ +21.35% | $2.40 (+32.77%) |
May 26, 2026 21w ago | 8-K | $3.57 $2.74 | ▲ +23.25% | ▲ +21.35% | $2.40 (+32.77%) |
May 26, 2026 21w ago | Press Release | $3.08 $2.83 | ▲ +8.12% | ▲ +6.17% | $2.40 (+22.08%) |
May 26, 2026 21w ago | 8-K | $3.08 $2.83 | ▼ −8.12% | ▼ −6.17% | $2.40 (−22.08%) |
May 26, 2026 21w ago | 424B5 | $3.08 $2.83 | ▲ +8.12% | ▲ +6.17% | $2.40 (+22.08%) |
May 26, 2026 21w ago | Press Release | $3.08 $2.83 | ▲ +8.12% | ▲ +6.17% | $2.40 (+22.08%) |
May 26, 2026 21w ago | Press Release | $3.08 $2.83 | ▼ −8.12% | ▼ −6.17% | $2.40 (−22.08%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers